The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium is a collaborative European project that comprises a programme to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. The European Medicines Agency (EMA) is the coordinator of PROTECT and GSK is the deputy co-ordinator of PROTECT. They manage a multi-national consortium of 34 partners including academics, regulators, SMEs and EFPIA companies.
PROTECT at ICPE 2014 - updates
PROTECT will present 13 posters, 8 oral presentations and 2 Symposiums at the 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management -ICPE, which will be held in Taipei (Taiwan, 24th - 27th October 2014).
New Publications for the PROTECT project
PROTECT has published two new articles respectively within the work programme on the Framework for pharmacoepidemiology studies (WP2) and the work programme on Benefit-Risk integration and representation (WP5).
You can find them in our Results section.
PROTECT 4th Periodic Project Report
The fourth PROTECT project periodic report covering the period 1 September 2012 to 31 August 2013, endorsed by the Innovative Medicines Initiative last December 2013, is now available on the PROTECT website. Please find a summary in the news section.
PROTECT at ICPE 2014
PROTECT has submitted 26 abstracts to the 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), which will be held in Taipei (Taiwan) from 24th to 27th October 2014. You can find more details here.
PROTECT WP2/WG3 has published the updated version of the Drug Consumption Databases
The authors have reviewed, compiled, and updated the knowledge about European sources of data on drug utilisation in the out- and inpatient healthcare setting. Information is available for Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Norway, Poland, Portugal, Slovenia, Spain, Sweden, The Netherlands, and The United Kingdom. Information was last updated December 2013.
Two documents are available. A master document organised as a scientific article, with a detailed and accurate account of the information already available, methods to retrieve this information, and a discussion. And, a country profile document with a summary of the relevant information from the masters document: country’s health system, reimbursement characteristics, and a list of websites of interest, summarised by country.
These documents are a shared resource for researchers, regulatory agencies, and pharmaceutical companies. They can be found here.